{"id":561806,"date":"2021-09-07T14:34:02","date_gmt":"2021-09-07T14:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=561806"},"modified":"2021-09-07T14:34:02","modified_gmt":"2021-09-07T14:34:02","slug":"osteosarcoma-epidemiology-forecast-report-2030-osteosarcoma-epidemiology-analysis-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-epidemiology-forecast-report-2030-osteosarcoma-epidemiology-analysis-2030-delveinsight_561806.html","title":{"rendered":"Osteosarcoma Epidemiology Forecast Report 2030 | Osteosarcoma Epidemiology Analysis 2030 | DelveInsight"},"content":{"rendered":"
\n
\"Osteosarcoma<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Osteosarcoma – Epidemiology Forecast\u20132030\u2019 report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Osteosarcoma Epidemiology Forecast, 2030.<\/a><\/strong><\/p>\n

Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones. The cancer cells in these tumors look like early forms of bone cells that normally help make new bone tissue, but the bone tissue in Osteosarcoma is not as strong as that of normal bones<\/p>\n

DelveInsight’s ‘Osteosarcoma Epidemiology Forecast to 2030‘<\/a> report delivers an in-depth understanding of the disease, historical and forecasted Osteosarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key highlights from the Osteosarcoma Epidemiology Report:<\/strong><\/p>\n

    \n
  1. \n

    As per DelveInsight analysts, the total incident population of osteosarcoma in the 7MM was  2,228  in 2020.<\/p>\n<\/li>\n

  2. \n

    The estimates show the highest incident cases of osteosarcoma in the United States with  1,174 cases in 2020.<\/p>\n<\/li>\n

  3. \n

    In 2020, out of the total incident population of  1,174 cases in the US, 620 and 554 cases were contributed by males and females, respectively. <\/p>\n<\/li>\n

  4. \n

    In 2020, age groups 0–24 years, 25–59 years, and >60 years accounted for 532, 297, and 345 cases, respectively, in the United States. <\/p>\n<\/li>\n<\/ol>\n

    Visit for more @ Osteosarcoma Epidemiology Insights<\/a><\/strong><\/p>\n

    Scope of the Osteosarcoma Epidemiology report:<\/strong><\/p>\n

      \n
    1. \n

      The Osteosarcoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns<\/p>\n<\/li>\n

    2. \n

      The Osteosarcoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Osteosarcoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<\/p>\n<\/li>\n

    3. \n

      The report provides insight into the historical and forecasted patient pool of Osteosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/p>\n<\/li>\n

    4. \n

      The report helps to recognize the growth opportunities in the 7MM concerning the patient population<\/p>\n<\/li>\n

    5. \n

      The report assesses the disease risk and burden and highlights the unmet needs of Osteosarcoma<\/p>\n<\/li>\n

    6. \n

      The report provides the segmentation of the Osteosarcoma epidemiology<\/p>\n<\/li>\n<\/ol>\n

      Table of Contents:<\/strong><\/p>\n

      1. Key Insights<\/p>\n

      2. Executive Summary of Osteosarcoma<\/p>\n

      3. Osteosarcoma Epidemiology Overview at a Glance<\/p>\n

      4. Osteosarcoma: Disease Background and Overview<\/p>\n

      5. Epidemiology and Patient Population<\/p>\n

      6. Case Reports<\/p>\n

      7. Country Wise-Epidemiology of Osteosarcoma <\/p>\n

      8. Appendix<\/p>\n

      9. DelveInsight Capabilities<\/p>\n

      10. Disclaimer<\/p>\n

      11. About DelveInsight<\/p>\n

      Related Reports:<\/strong><\/p>\n

      Osteosarcoma Market<\/a><\/strong><\/p>\n

      DelveInsight’s ‘Osteosarcoma-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), <\/p>\n

      Osteosarcoma Pipeline <\/a><\/strong><\/p>\n

      “Osteosarcoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Osteosarcoma market. A detailed picture of the Osteosarcoma pipeline landscape is provided, which includes the disease overview and Osteosarcoma treatment guidelines.<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight\u2019s \u2018Osteosarcoma – Epidemiology Forecast\u20132030\u2019 report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-561806","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=561806"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=561806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=561806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=561806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}